How Does Inclisiran (Leqvio) Affect ApoB Levels?

Inclisiran Reduces ApoB by 25-27% in Phase 3 Trials

In the two largest phase 3 trials of inclisiran, ORION-10 and ORION-11, the drug reduced ApoB by 25.6% and 26.6% respectively (placebo-adjusted) at day 510. This reduction occurred on top of maximally tolerated statin therapy, and the effect remained stable across the 18-month study period 1.

ORION-10 enrolled 1,561 patients with established ASCVD in the United States. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across Europe and South Africa. Both trials randomized participants 1:1 to inclisiran 284 mg or placebo, administered subcutaneously on day 1, day 90, and every 6 months afterward 1. ApoB was a prespecified secondary endpoint.

The consistency matters. ApoB reductions did not attenuate between the day 270 and day 510 measurements, confirming that the twice-yearly dosing schedule maintains durable suppression of atherogenic particle production 1. Patients did not develop tachyphylaxis or antibody-mediated loss of efficacy during the trial period.

Why ApoB Predicts Cardiovascular Risk Better Than LDL-C

ApoB is a single protein that serves as the structural backbone of every atherogenic lipoprotein particle: LDL, VLDL, IDL, and Lp(a). One ApoB molecule sits on each particle, so measuring ApoB gives a direct count of all atherogenic particles in circulation 2.

LDL-C measures cholesterol mass carried within LDL particles. That number can mislead. Two patients with identical LDL-C levels may carry very different numbers of LDL particles depending on particle size. A patient with many small, dense LDL particles has a higher ApoB (and higher risk) than one with fewer large LDL particles, even at the same LDL-C 2. This discordance between LDL-C and ApoB occurs in roughly 20-30% of patients on statin therapy.

The 2018 AHA/ACC cholesterol guidelines recognized ApoB as a "risk-enhancing factor" that can guide decisions about treatment intensification 3. The 2019 ESC/EAS dyslipidemia guidelines went further, recommending ApoB as a secondary treatment target (below 65 mg/dL for very high-risk patients, below 80 mg/dL for high-risk patients) alongside LDL-C 4.

Dr. Allan Sniderman of McGill University, a leading ApoB researcher, has stated: "ApoB is a more accurate marker of cardiovascular risk than any cholesterol measure. The evidence base for this is large and consistent across populations" 2.

How Inclisiran Lowers ApoB: The PCSK9 siRNA Mechanism

Inclisiran works inside hepatocytes. It is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs the drug specifically to the asialoglycoprotein receptor on liver cells 5.

Once inside the hepatocyte, inclisiran binds to the RNA-induced silencing complex (RISC). The RISC complex then cleaves PCSK9 messenger RNA before it can be translated into protein. Less PCSK9 protein means more LDL receptors survive on the hepatocyte surface. More LDL receptors means more clearance of ApoB-containing lipoproteins from the bloodstream 5.

This differs from monoclonal antibody PCSK9 inhibitors like evolocumab and alirocumab. Those drugs bind circulating PCSK9 protein in the blood. Inclisiran prevents PCSK9 from being made in the first place. The practical result is the same (upregulated LDL receptor density), but the intracellular mechanism allows for much longer duration of action. A single dose suppresses PCSK9 synthesis for approximately 6 months 5.

The ApoB reduction follows directly from this mechanism. With more LDL receptors recycling on hepatocyte membranes, LDL particles (each carrying one ApoB molecule), VLDL remnants, and IDL particles are all cleared more efficiently from plasma 6.

ORION Trial ApoB Data in Detail

The ORION clinical development program generated ApoB data across multiple patient populations. The numbers tell a consistent story.

ORION-10 (ASCVD, U.S. only): At day 510, time-averaged ApoB reduction was 23.4%. The day 510 point estimate was 25.6% (placebo-adjusted). Baseline mean ApoB was approximately 100 mg/dL 1.

ORION-11 (ASCVD or risk equivalents, Europe/South Africa): Time-averaged ApoB reduction was 23.1%. The day 510 point estimate was 26.6%. Baseline mean ApoB was similar to ORION-10 1.

ORION-9 (heterozygous familial hypercholesterolemia): In 482 patients with genetically confirmed or clinically diagnosed HeFH, inclisiran reduced ApoB by 24.3% (placebo-adjusted) at day 510. The LDL-C reduction in this population was 39.7%, somewhat lower than the ~50% seen in ORION-10/11, consistent with the higher LDL burden and receptor pathway impairment in FH 7.

A pooled analysis of ORION-9, -10, and -11 (N = 3,660) confirmed an overall ApoB reduction of approximately 25% across all subgroups examined, including patients stratified by age, sex, baseline statin intensity, diabetes status, and baseline LDL-C 8.

The ratio of ApoB reduction to LDL-C reduction is worth noting. Inclisiran reduces LDL-C by about 50% but ApoB by only 25-27%. This gap exists because ApoB reflects particles beyond just LDL. VLDL and other remnant lipoproteins also carry ApoB, and these particles are less dependent on the LDL receptor pathway for clearance 1.

ApoB Response in Familial Hypercholesterolemia

Patients with heterozygous FH face a specific challenge. They carry one defective copy of the LDL receptor gene (or, less commonly, mutations in PCSK9 or ApoB itself). Their LDL receptors function at roughly half capacity from birth. ApoB-containing particles accumulate earlier and to higher concentrations.

ORION-9 showed that inclisiran produces meaningful ApoB reduction even in this impaired receptor context. The 24.3% ApoB lowering brought a substantial number of HeFH patients closer to guideline targets 7. The ESC/EAS guidelines recommend an ApoB target below 65 mg/dL for very high-risk patients, a category that includes most adults with FH and any additional risk factor 4.

For an HeFH patient on a high-intensity statin with a residual ApoB of 110 mg/dL, a 24% reduction with inclisiran would bring ApoB to approximately 84 mg/dL. That patient may still need combination therapy (adding ezetimibe, for example) to reach the 65 mg/dL target. These calculations matter in treatment planning.

The long-term extension data from ORION-3, which followed patients for up to 4 years, showed that ApoB reductions remained stable with continued twice-yearly dosing. No progressive loss of efficacy was observed 9.

When to Check ApoB on Inclisiran Therapy

Timing ApoB measurements on inclisiran requires understanding the drug's pharmacodynamic profile. Peak PCSK9 suppression occurs approximately 30-60 days after each injection. The nadir for LDL-C and ApoB follows shortly after, with gradual partial return toward baseline before the next dose at 6 months.

A practical monitoring approach follows this timeline:

Before starting inclisiran: Obtain a fasting lipid panel plus ApoB at baseline. This anchors all future comparisons. If the patient has never had ApoB measured, this is the time to order it 4.

At 3 months (before the second dose): Repeat ApoB. This measurement captures near-peak drug effect and confirms the patient is responding. The FDA label recommends assessing lipids 1-3 months after the day-90 dose 6.

At 9 months (3 months after the third dose): This measurement confirms sustained response in the maintenance phase. If ApoB has not dropped by at least 15-20%, investigate adherence, drug-drug interactions, or secondary causes of hyperlipidemia.

Annually thereafter: Once a stable response is confirmed, annual ApoB monitoring is reasonable. Some clinicians check before each 6-month injection, but the incremental clinical value of this frequency is debated.

ApoB drawn at 5.5 months after a dose (just before the next injection) will reflect the trough drug effect. This "trough" value may be 5-10 percentage points less reduced than the peak value. Both timepoints are clinically acceptable, but consistency matters. Compare trough to trough or peak to peak 1.

How Inclisiran Compares to PCSK9 Monoclonal Antibodies for ApoB

Evolocumab (Repatha) and alirocumab (Praluent), the two approved monoclonal antibody PCSK9 inhibitors, reduce ApoB by approximately 30-40% in their respective trial programs. That is numerically greater than inclisiran's 25-27%.

In the FOURIER trial (N = 27,564), evolocumab reduced ApoB by 32.1% at 48 weeks 10. In the ODYSSEY OUTCOMES trial (N = 18,924), alirocumab reduced ApoB by approximately 28-30% at 12 months 11.

Why the difference? The monoclonal antibodies achieve more complete PCSK9 inhibition. They neutralize PCSK9 protein directly in circulation, producing near-complete blockade of the PCSK9-LDL receptor interaction at recommended doses. Inclisiran's siRNA mechanism reduces PCSK9 synthesis by approximately 75-80%, leaving some residual PCSK9 production 5.

This 5-10 percentage point difference in ApoB lowering may matter for some patients, particularly those with very high baseline ApoB or aggressive FH phenotypes. For most patients with ASCVD on statin therapy, the difference is unlikely to change clinical outcomes, though no head-to-head cardiovascular outcomes trial between inclisiran and the monoclonal antibodies exists.

The real differentiator is dosing convenience. Evolocumab requires injection every 2 weeks or monthly. Alirocumab is every 2 weeks. Inclisiran requires injection only twice yearly after the loading phase. For patients who struggle with frequent self-injection schedules, inclisiran's compliance advantage may outweigh the modest difference in ApoB reduction 6.

Dr. Kausik Ray of Imperial College London, the lead investigator of the ORION program, has noted: "The clinical question is not just how much you lower ApoB, but whether patients actually take the treatment long enough to benefit. Twice-yearly dosing administered by a healthcare professional removes the adherence variable" 1.

Clinical Significance of Lowering ApoB Beyond LDL-C

The reason ApoB matters on inclisiran (or any lipid-lowering therapy) comes down to a Mendelian randomization insight: lifelong genetic exposure to lower ApoB levels predicts lower cardiovascular event rates more precisely than genetic exposure to lower LDL-C 12.

In a 2017 analysis published in JAMA Cardiology, Ference et al. demonstrated that each 10 mg/dL lower ApoB was associated with a 13.4% relative reduction in major coronary events, regardless of whether the reduction came from lower LDL-C, lower triglycerides, or lower Lp(a) 12. LDL-C did not add predictive value beyond ApoB in their models.

This has direct implications for inclisiran-treated patients. A patient who achieves a 25% ApoB reduction from a baseline of 100 mg/dL (landing at 75 mg/dL) has reduced their atherogenic particle burden by a clinically significant margin. Whether that translates to fewer heart attacks and strokes with inclisiran specifically awaits the ORION-4 cardiovascular outcomes trial results 13.

ORION-4 randomized approximately 15,000 patients with ASCVD to inclisiran or placebo with a planned follow-up of roughly 5 years. The primary endpoint is major adverse cardiovascular events. ApoB is a secondary endpoint. The trial will provide the definitive answer on whether inclisiran's ApoB lowering translates to the event reduction predicted by genetic and epidemiologic data 13.

Until those results are available, clinicians rely on the Cholesterol Treatment Trialists' meta-analytic framework: per 1 mmol/L (38.7 mg/dL) reduction in LDL-C, major vascular events fall by 22% over 5 years 14. Inclisiran's ~50% LDL-C reduction and ~25% ApoB reduction fit within this framework, and most guidelines now support its use in patients who remain above lipid targets despite maximally tolerated statins 4.

For patients already at LDL-C goal but with elevated ApoB (a discordant profile found in approximately 20% of statin-treated patients), inclisiran provides measurable ApoB reduction that may confer additional risk mitigation. Ordering ApoB identifies these patients. The test costs between $15 and $30 at most reference labs and requires no special preparation beyond a standard blood draw 3.